O6 Dissecting the shift in YAP/TAZ signalling modalities with disease progression in cancer-associated fibroblasts of cutaneous squamous cell carcinoma

Clicks: 1
ID: 318458
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #257 of 302 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 302 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction and aims Cancer-associated fibroblasts (CAFs) can promote or supress tumour growth. Yes-associated protein/transcriptional coactivator with PDZ-binding motif (YAP/TAZ) signalling is often dysregulated in cancers, including cutaneous squamous cell carcinoma (cSCC), and YAP-transcriptional enhanced associated domain (TEAD) inhibitors are in clinical trials for cancers. Little is known about YAP/TAZ signalling in CAFs during cancer progression and how inhibition affects CAF phenotype. Using isogenic fibroblast lines isolated in our lab from normal skin tissue, primary tumour, and recurrent tumour, we aim to dissect the distinct YAP/TAZ signalling modalities in CAFs. We hypothesize that YAP/TAZ signals through different cofactors in cancer cells and CAFs and that targeted inhibition will affect these cell types differently during cSCC progression. Methods Changes in YAP/TAZ signalling with disease progression were assessed using assay for transposase-accessible chromatin (ATAC)/RNA sequencing (RNAseq) datasets, two-dimensional and three-dimensional skin coculture models, YAP/TAZ transient knockdowns, and YAP-TEAD inhibitor treatment as a discovery tool. Results Immunofluorescent staining of cSCC tissue shows increased stromal YAP/TAZ expression, and RNAseq and reverse transcriptase quantitative polymerase chain reaction data confirmed YAP/TAZ signalling in CAFs increases with disease progression. While YAP/TAZ signal through TEADs in cSCC keratinocytes, analysis of ATAC/RNAseq data indicates a shift in association of YAP/TAZ between TEAD and activator protein (AP)-1 in our CAF progression series. Accessibility of AP-1 binding motifs peaks in primary CAFs, and TEAD motif accessibility peaks in recurrent CAFs. While normal fibroblasts respond strongly to TEAD-specific inhibition, impacting proliferation, contraction and extracellular matrix remodelling, CAFs become less responsive with disease progression, providing further evidence of a signalling switch. We are currently investigating how this switch influences CAF–cancer cell crosstalk by modulating YAP-TEAD and AP-1 signalling in three-dimensional organotypic cocultures. Conclusions These results suggest YAP/TAZ signalling is altered in CAFs and evolves with disease progression. A switch in association of YAP/TAZ with downstream transcription factors could affect efficacy of TEAD inhibitors in clinical development at different stages of cSCC.
Reference Key
openalex_W7165625505 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Maria Moran, Tjaša Bensa, Gernot Walko, Emanuel Rognoni
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag151.006
URL
https://doi.org/10.1093/bjd/ljag151.006
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.